Kawasaki Disease



Kawasaki disease, or mucocutaneous lymph node syndrome, was first described in Japan in the late 1960s as an illness characterized by persistent fever, conjunctivitis, mucous membrane changes, acral erythema with desquamation, and cervical adenopathy, associated with coronary arteritis (1,2). While earlier descriptions of the disease were limited to Asia and Hawaii, the disease is now known to occur worldwide. The disease is primarily one of young children, with 85% of cases occurring in children under five years. It is uncommon in children less than 6 months. There have been some epidemiologic investigations linking Kawasaki disease to freshly cleaned carpets, humidifier use, and living near a body of water, but these associations have not been observed consistently (3).


Kawasaki Disease Scarlet Fever Coronary Aneurysm Coronary Magnetic Resonance Angiography Kawasaki Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kawasaki T. Mucocutaneous lymph node syndrome: Clinical observation of 50 cases. Jpn J Allerg 1967;16:178–222 (in Japanese)Google Scholar
  2. 2.
    Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–276.PubMedGoogle Scholar
  3. 3.
    Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533–544.PubMedCrossRefGoogle Scholar
  4. 4.
    Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499–502.PubMedCrossRefGoogle Scholar
  5. 5.
    Rowley AH, Eckerly CA, Hans-Martin J, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946–5955.PubMedGoogle Scholar
  6. 6.
    Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334–1343.PubMedGoogle Scholar
  7. 7.
    Friter BS, Lucky AW. The perineal eruption of Kawasaki syndrome. Arch Dermatol 1988;124:1805–1810.PubMedCrossRefGoogle Scholar
  8. 8.
    Kimura T, Miyazawa H, Watanabe K, Moriya T. Small pustules in Kawasaki disease: A clinicopathological study of four patients. Am J Dermatopathol 1988;10:218–223.PubMedCrossRefGoogle Scholar
  9. 9.
    Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with Kawasaki disease. Circulation 2002;105:908–911.PubMedCrossRefGoogle Scholar
  10. 10.
    Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: Use of clinical features and a rapid direct fluorescent antigen test. Arch Pediatr Adolesc Med 2000;154:453–456.PubMedGoogle Scholar
  11. 11.
    Jennette JC. Implications for pathogenesis patterns of injury in small-and medium-sized-vessel vasculitis. Cleveland Clin J Med 2003;69: SII-33–38.Google Scholar
  12. 12.
    Terai M, Yasukawa K, Honda T. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002;8:777–781.Google Scholar
  13. 13.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341–347.PubMedCrossRefGoogle Scholar
  14. 14.
    Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:645S–687S.PubMedCrossRefGoogle Scholar
  15. 15.
    Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: An evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86:286–290.PubMedCrossRefGoogle Scholar
  16. 16.
    Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888–893.PubMedCrossRefGoogle Scholar
  17. 17.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of Kawasaki disease: Aspirin’s role in the febrile stage revisited. Pediatrics 2004;114:689–693.CrossRefGoogle Scholar
  18. 18.
    Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463–464.PubMedCrossRefGoogle Scholar
  19. 19.
    Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 2004;89:776–780.PubMedCrossRefGoogle Scholar
  20. 20.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808–810.PubMedGoogle Scholar
  21. 21.
    Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: Report of a randomized trial. J Pediatr 2003;142:611–616.PubMedCrossRefGoogle Scholar
  22. 22.
    Kato H, Sugimura T, Akagi T, et al. Long term consequences of Kawasaki disease. Circulation 1996;94:1379–1385.PubMedGoogle Scholar
  23. 23.
    Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: Association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Michie C, Kinsler V, Tulloh R, Davidson S. Recurrent skin peeling following Kawasaki disease. Arch Dis Child 2000;83:353–355.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Personalised recommendations